Evonik's Next Catalyst Sits With Its Biggest Shareholder, Not a Suitor
Published on 11/21/2026 at 06:40 | Editorial boerse-global.deEvonik's investors have spent the week recalibrating what the specialty chemicals maker is worth on its own. The answer, as it stands, hinges less on any revived takeover talk than on whether its largest shareholder converts a vague commitment into a binding one — and whether that step comes attached to money for the business.
The stock closed yesterday at EUR 18.18, well below the EUR 24 per share BASF floated in its final non-binding cash offer. That gap is not latent takeover upside; it is simply the distance between the last bid on the table and a market that no longer expects one, now that no fresh offer exists.
Two Offers Declined, One Suitor Gone
Evonik turned down two unsolicited all-cash approaches, the second of which would have valued the company at roughly EUR 11.2 billion. BASF walked away this week, citing in part its failure to secure access to a deeper round of due diligence. Interim chief executive Claus Rettig has made clear he intends to press on with Evonik's standalone growth plan.
That leaves the field to Bernstein analyst James Hooper's scenario, reported in the media yesterday, under which the two sides could eventually return to the table. His condition is specific: Evonik would have to approach BASF and demonstrate a value above EUR 24 a share. Hooper frames this as a possibility, not a forecast of a renewed bid.
What the Union Wants From the RAG-Stiftung
The more immediate pressure comes from IG BCE. The union called yesterday, according to Handelsblatt, for the RAG-Stiftung to anchor its targeted minimum stake of 25.1% permanently in Evonik's articles of association and to give the company more room to invest. It also took aim at the foundation's dividend policy to date.
Should investors sell immediately? Or is it worth buying Evonik?
The RAG-Stiftung is Evonik's largest shareholder and reaffirmed yesterday its intention to whittle its holding down to 25.1% over time. Per dpa-AFX, it would also have welcomed a deeper exchange between the two companies' boards over the takeover that BASF abandoned on Thursday. The foundation is selling down to fund the long-term costs of Germany's hard-coal mining legacy and to build up other capital investments.
For shareholders, the distinction between a target ratio and a constitutional floor matters. The 25.1% figure describes where the foundation intends to end up; the union is demanding a permanent lower bound. Even if the foundation embraced that demand, it would settle only the ownership question. Whether Evonik could then invest more is a separate judgment — and that is the yardstick by which any decision should be measured.
A Production Milestone, Off to the Side
Operational progress is arriving on its own track. On 10 November Evonik reported the first product batch from its new Lipid Innovation Center in Lafayette, Indiana, where pharmaceutical lipids are to be made under good manufacturing practice standards. The batch is a tangible manufacturing step, though not a measure of the site's eventual economic contribution. It illustrates the kind of project-level advance investors can assess independently of the ownership debate.
Where the Analysts Have Landed
Brokerage reactions since BASF's retreat show the market pricing Evonik as a standalone business, without a consensus target. ODDO BHF cut the stock yesterday to "Neutral" from "Outperform" and trimmed its price target to EUR 19 from EUR 22, pointing to the collapse of the takeover effort. Jefferies was unmoved, keeping Evonik at "Hold" on Thursday with a EUR 21 target. Both stances are cautious, and the spread between the targets offers no common read on what extra investment headroom would be worth.
The bear case is a gradual sell-down that never produces a concrete investment commitment. In that world, reaffirming the 25.1% goal would justify no additional financial leeway in anyone's model. BASF itself said Evonik's standalone prospects and risks did not warrant a higher valuation.
The Next Concrete Test
Until the foundation moves beyond restating its sell-down target, investors should treat the prospect of greater investment capacity as a scenario rather than a fact. A binding floor would, at first, buy clarity on ownership alone. A genuine re-rating on operating grounds would need that step paired with firm commitments on spending.
The next tangible trigger, then, is the foundation's response to the demand for a constitutional anchor and for investment room. What counts is whether it merely reaffirms the existing target or names a step that reaches past the ownership question. Political headwinds, meanwhile, were reported by the Frankfurter Allgemeine Zeitung to have weighed heavily on BASF's decision to withdraw; North Rhine-Westphalia premier Hendrik Wüst pointed to the 11,000 Evonik jobs in the state, and BASF had already offered protections for sites, research and employment in Germany through 2032. The foundation's regret at the absence of deeper board talks does not amount to backing a sale on the terms offered — and its wish for dialogue substitutes for neither Evonik's willingness to engage nor BASF's readiness to pay more.
Ad
Evonik Stock: New Analysis - 21 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
